Aurinia Pharmaceuticals Inc. (AUPH) · Aug 19, 2026 · Material agreement

Aurinia settles Teva patent fight, but generic launch timing remains undisclosed

Patent settlement — Settlement terms, payment details, and generic launch date not disclosed

Aurinia resolves Teva’s voclosporin patent litigation, removing courtroom uncertainty—but the filing reveals no launch date or settlement economics.

The legal overhang is resolved, but the financial read is incomplete. Aurinia and Teva entered a settlement covering Teva’s proposed generic 7.9 mg voclosporin capsules. 〔0〕 (8-K narrative)

This is not yet a clean win versus expectations. The filing confirms the dispute is settled, but provides no agreed generic launch date, payment to Aurinia, royalty, supply arrangement, or other economic term. Without those details, the market cannot determine from this filing whether Teva is delayed until patent expiry or gains an earlier commercial entry.

ItemFiling disclosure
CounterpartyTeva Pharmaceuticals Inc. (8-K narrative)
Product affectedGeneric 7.9 mg voclosporin oral capsules (8-K narrative)
PurposeResolve patent infringement litigation (8-K narrative)
Settlement economicsNot disclosed
Generic launch timingNot disclosed

The immediate change is lower litigation uncertainty, not a quantified upgrade to LUPKYNIS economics. The settlement removes the binary risk of a court outcome, but the absent commercial terms leave the most important investor question—when generic competition can begin—unanswered. Relative to the standing expectation, this is best classified as a new but incomplete event rather than a substantiated beat or miss.

Original filing on SEC EDGAR

More Aurinia Pharmaceuticals Inc. news

Aurinia settles Teva patent fight, but generic launch timing remains undisclosed | AUPH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.